抗 CD22/CD19 CAR-T 细胞疗法 CART2219.1 在成人和儿童复发/难治性 B-ALL 中的 I/II 期试验
A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.
在一项多中心I/II期试验中,所有患者(n=11;7名儿童,4名成人)在第28天均达到完全缓解(91%为微小残留病阴性)。
英文原题:Characterization of mesenchymal stem cells in pre-B acute lymphoblastic leukemia.
本研究为 MSCs 在 B-ALL 进展过程中的作用提供了细胞与分子层面的见解。
骨髓微环境(BMM)成分可影响白血病的发生、进展及治疗反应。越来越多证据显示,白血病细胞会劫持BMM,改变其功能,并与基质细胞和免疫细胞建立支持白血病的相互作用。既往研究已指出急性白血病BMM中间充质干细胞(MSC)群体存在功能缺陷,但尚未对前B细胞急性淋巴细胞白血病(B-ALL)中的MSC(B-ALL是儿童最常见癌症)开展全面表征和分子分析。本研究调查了从具有免疫功能的BCR-ABL1⁺ B-ALL模型骨髓微环境分离的MSC细胞和转录组特征。白血病相关MSC体外自我更新能力降低,多种分子特征显著改变,包括炎症信号通路上调。此外,白血病相关MSC中参与细胞外基质组织和成骨细胞生成的基因下调。本研究提供了MSC在B-ALL进展中作用的细胞和分子层面认识。
Components of the bone marrow microenvironment (BMM) have been shown to mediate the way in which leukemia develops, progresses and responds to treatment. Increasing evidence shows that leukemic cells hijack the BMM, altering its functioning and establishing leukemia-supportive interactions with stromal and immune cells. While previous work has highlighted functional defects in the mesenchymal stem cell (MSC) population from the BMM of acute leukemias, thorough characterization and molecular profiling of MSCs in pre-B cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children, has not been conducted. Here, we investigated the cellular and transcriptome profiles of MSCs isolated from the BMM of an immunocompetent BCR-ABL1 + model of B-ALL. Leukemia-associated MSCs exhibited reduced self-renewal capacity in vitro and significant changes in numerous molecular signatures, including upregulation of inflammatory signaling pathways. Additionally, we found downregulation of genes involved in extracellular matrix organization and osteoblastogenesis in leukemia-associated MSCs. This study provides cellular and molecular insights into the role of MSCs during B-ALL progression.
MEMBER ACCOUNT
登录成功会直接打开下一页。